Martin Shkreli, the “pharma bro” entrepreneur who astronomically increased the price of a life-saving drug by more than 4,000% and became a symbol of corporate Wall Street greed, cannot return to the pharmaceutical industry, a court has ruled.
A federal appeals court in New York upheld his lifetime ban from the business.
